Evidence map›Paper›PMID 30385157›Full record

SynthesisThe Lancet. Infectious diseases2018

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.

Jack Stone, Hannah Fraser, Aaron G Lim, Josephine G Walker, Zoe Ward, Louis MacGregor, Adam Trickey, Sam Abbott, Steffanie A Strathdee, Daniela Abramovitz and 33 more

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Lancet. Infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 12 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 12 syntheses or guidelines pooled it, 220 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors at 20 institutions in 9 countries.

Jack StonePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: jack.stone@bristol.ac.uk.
Hannah FraserPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Aaron G LimPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Josephine G WalkerPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Zoe WardPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Louis MacGregorPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Adam TrickeyPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Sam AbbottPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Steffanie A StrathdeeDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA.
Daniela AbramovitzDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA.
Lisa MaherKirby Institute for Infection and Immunity, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Jenny IversenKirby Institute for Infection and Immunity, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Julie BruneauDepartment of Family Medicine, Université de Montréal, Montréal, QC, Canada; Centre hospitalier de l'Université de Montreal, Montréal, QC, Canada.
Geng ZangCentre hospitalier de l'Université de Montreal, Montréal, QC, Canada.
Richard S GarfeinDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA.
Yung-Fen YenSection of Infectious Diseases, Taipei City Hospital, Taipei City Government, Taipei, Taiwan.
Tasnim AzimJames P Grant School of Public Health, BRAC University, Dhaka, Bangladesh.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Michael-John MilloyBC Centre for Excellence in HIV/AIDS and Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Margaret E HellardBurnet Institute, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Rachel Sacks-DavisBurnet Institute, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
Paul M DietzeBurnet Institute, Melbourne, VIC, Australia.
Campbell AitkenBurnet Institute, Melbourne, VIC, Australia.
Malvina AladashviliInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.
Tengiz TsertsvadzeInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia; Faculty of Medicine, Tbilisi State University, Tbilisi, Georgia.
Viktor MravčíkNational Monitoring Centre for Drugs and Addiction, Prague, Czech Republic; Department of Addictology, The First Medical Faculty, Charles University and General University Hospital in Prague, Prague, Czech Republic; National Institute of Mental Health, Klecany, Czech Republic.
Michel AlaryUniversity Hospital Centre of Québec Research Centre-Laval University, QC, Canada; National Institute of Public Health of Québec, QC, Canada.
Elise RoyNational Institute of Public Health of Québec, QC, Canada; Faculty of Medicine and Health Sciences, University of Sherbrooke, Longueuil, QC, Canada.
Pavlo SmyrnovInternational Charitable Foundation Alliance for Public Health, Kiev, Ukraine.
Yana SazonovaInternational Charitable Foundation Alliance for Public Health, Kiev, Ukraine.
April M YoungDepartment of Epidemiology, University of Kentucky College of Public Health, KY, USA; Center on Drug and Alcohol Research, University of Kentucky, KY, USA.
Jennifer R HavensCenter on Drug and Alcohol Research, University of Kentucky, KY, USA.
Vivian D HopePublic Health Institute, Liverpool John Moores University, Liverpool, UK; National Infection Service, Public Health England, London, UK.
Monica DesaiNational Infection Service, Public Health England, London, UK.
Ellen HeinsbroekNational Infection Service, Public Health England, London, UK.
Sharon J HutchinsonSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, National Health Service National Services Scotland, Glasgow, UK.
Norah E PalmateerSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, National Health Service National Services Scotland, Glasgow, UK.
Andrew McAuleySchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Lucy PlattFaculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Natasha K MartinPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA.
Frederick L AlticeYale School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA.
Matthew HickmanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Peter VickermanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
University of Bristol · GBBurnet Institute · AUPublic Health England · GBUniversity of California San Diego · USAlliance for Public Health · UAGlasgow Caledonian University · GBUniversity of Kentucky · USUNSW Sydney · AUAIDS and Clinical Immunology Research Center · GEBRAC University · BDCentre Hospitalier de l’Université de Montréal · CAHealth Protection Scotland · GBJohns Hopkins University · USLondon School of Hygiene & Tropical Medicine · GBMonash University · AUNational Institute of Mental Health · CZTaipei Municipal YangMing Hospital · TWTbilisi State University · GEUniversité de Montréal · CAUniversité de Sherbrooke · CA

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
INCIDENCE OF HIV INFECTIONS IN A COHORT OF IV DRUG USERSR01DA012568 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MEHTA, SHRUTI H · 1999 to 2017
$15.5M
Prison Interventions and HIV Prevention CollaborationR01DA029910 · NIDA · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE · 2010 to 2026
$7.9M
Examining the Impact of the Twin Epidemics of Methamphetamine and Opioid Use on Overdose, Risky Sex and Treatment Engagement among PWUD in Two Rural Appalachian CohortsR01DA033862 · NIDA · UNIVERSITY OF KENTUCKY · PI Jennifer R Havens · 2012 to 2026
$6.9M
Impact of Drug Policy Reform on the HIV Risk Environment among IDUs in TijuanaR37DA019829 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2010 to 2019
$6.7M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
Integrating Addiction Treatment and HIV Services into Primary Care Clinics in UkraineR01DA043125 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2016 to 2021
$4.4M
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice PopulationsR01DA030762 · NIDA · YALE UNIVERSITY · PI SPRINGER, SANDRA ANN · 2010 to 2015
$4.1M
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice SettingsR01DA041271 · NIDA · YALE UNIVERSITY · PI SHENOI, SHEELA · 2016 to 2021
$3.3M
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUsR01DA031074 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARFEIN, RICHARD S · 2011 to 2015
$3.2M
Social networks and HIV risk among rural drug usersR01DA024598 · NIDA · UNIVERSITY OF KENTUCKY · PI HAVENS, JENNIFER R · 2008 to 2012
$2.6M
Department of Health 12/3070/13Department of Health RP-PG-0616-20008NIAID NIH HHS P30 AI036214NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA012568NIDA NIH HHS R01 DA024598NIDA NIH HHS R01 DA029910NIDA NIH HHS R01 DA030762NIDA NIH HHS R01 DA031074NIDA NIH HHS R01 DA033679NIDA NIH HHS R01 DA033862NIDA NIH HHS R01 DA037773NIDA NIH HHS R01 DA041271NIDA NIH HHS R01 DA043125NIDA NIH HHS R21 DA041953NIDA NIH HHS R21 DA042702NIDA NIH HHS R37 DA019829NIDA NIH HHS U01 DA036297
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) experience a high prevalence of incarceration and might be at high risk of HIV and hepatitis C virus (HCV) infection during or after incarceration. We aimed to assess whether incarceration history elevates HIV or HCV acquisition risk among PWID.

methodsIn this systematic review and meta-analysis, we searched MEDLINE, Embase, and PsycINFO databases for studies in any language published from Jan 1, 2000 until June 13, 2017 assessing HIV or HCV incidence among PWID. We included studies that measured HIV or HCV incidence among community-recruited PWID. We included only studies reporting original results and excluded studies that evaluated incident infections by self-report. We contacted authors of cohort studies that met the inclusion or exclusion criteria, but that did not report on the outcomes of interest, to request data. We extracted and pooled data from the included studies using random-effects meta-analyses to quantify the associations between recent (past 3, 6, or 12 months or since last follow-up) or past incarceration and HIV or HCV acquisition (primary infection or reinfection) risk among PWID. We assessed the risk of bias of included studies using the Newcastle-Ottawa Scale. Between-study heterogeneity was evaluated using the I

findingsWe included published results from 20 studies and unpublished results from 21 studies. These studies originated from Australasia, western and eastern Europe, North and Latin America, and east and southeast Asia. Recent incarceration was associated with an 81% (relative risk [RR] 1·81, 95% CI 1·40-2·34) increase in HIV acquisition risk, with moderate heterogeneity between studies (I

interpretationIncarceration is associated with substantial short-term increases in HIV and HCV acquisition risk among PWID and could be a significant driver of HCV and HIV transmission among PWID. These findings support the need for developing novel interventions to minimise the risk of HCV and HIV acquisition, including addressing structural risks associated with drug laws and excessive incarceration of PWID.

fundingEngineering and Physical Sciences Research Council, National Institute for Health Research, National Institutes of Health.

Indexed as

PrisonersAdultAgedAged, 80 and overAmericasAsia, SoutheasternAustralasiaDisease Transmission, InfectiousEuropeFemaleHepatitis CHIV InfectionsHumansMaleMiddle AgedPrevalence

Identifiers

PMID30385157
PMCPMC6280039
OpenAlexW2884203623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.